Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
View Patent ↗Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as initable bowel syndrome, Cnohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar depression, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are described.
1. A method of treating pain in a patient in need thereof comprising administering to said patient an effective amount of a compound represented by Formula (IA) or (IB):
or a pharmaceutically acceptable salt thereof, wherein
X is —S—;
R 1 is hydrogen, —C 1-4 alkyl, —C 1-4 alkyl-N(C 0-4 alkyl)(C 0-4 alkyl), —C 0-4 alkyl-CO—N(C 0-4 alkyl)(C 0-4 alkyl), —C 0-4 alkyl-CO—O(C 0-4 alkyl), —C 1-4 alkyl-piperidinyl, —C 1-4 alkyl-morpholinyl, —C 1-4 alkyl-pyrrolidinyl, —C 1-4 alkyl-aryl, —C 1-4 alkyl-aryl-aryl, optionally substituted with 1-6 independent halogen, —CN, —NO 2 , —C 1-4 alkyl, —O—C 1-4 alkyl, —N(C 0-4 alkyl)(C 0-4 alkyl), —C 0-4 alkyl-CO—O(C 0-4 alkyl), —(C 0-4 alkyl)-NH—CO—O(C 0-4 alkyl), —(C 0-4 alkyl)-CO—N(C 0-4 alkyl)(C 0-4 alkyl), —S(C 0-4 alkyl), —S(O)(C 1-4 alkyl), —SO 2 (C 1-4 alkyl), —SO 2 N(C 0-4 alkyl)(C 0-4 alkyl), or —NHSO 2 (C 1-4 alkyl) substituents;
R 2 is —C 0-4 alkyl;
Ar 1 is phenyl, optionally substituted with 1-4 independent i) halogen, ii) —CN, iii) —NO 2 , iv) —CHO, v) —O—C 1-4 alkyl, vi) —N(C 0-4 alkyl)(C 0-4 alkyl), vii) —C 0-4 alkyl-CO—O(C 0-4 alkyl), viii) —(C 0-4 alkyl)-NH—CO—O(C 0-4 alkyl), ix) —(C 0-4 alkyl)-CO—N(C 0-4 alkyl)(C 0-4 alkyl), x) —S(C 0-4 alkyl), xi) —S(O)(C 1-4 alkyl), xii) —SO 2 (C 1-4 alkyl), xiii) —SO 2 N(C 0-4 alkyl)(C 0-4 alkyl), xiv) —NHSO 2 (C 1-4 alkyl), xv) —C 1-10 alkyl optionally substituted with 1-6 independent —CHO, —O—C 1-4 alkyl, aryl, aryloxy-, —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)-C(O)—(C 0-6 alkyl), —OPO(OH)O-M + , —OSO 3 -M + , —O—CO(C 1-3 alkyl)CO 2 M + , —O—CO—(C 1-6 alkyl)-N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—C 0-6 alkyl, —N(C 0-6 alkyl)-C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), xvi) —C 1-10 alkyl in which one or more of the alkyl carbons is replaced by a —N(C 0-6 alkyl)-, —O—, —S(O) 1,2 —, —O—O(O)—, —C(O)——C(O)—N(C 0-6 alkyl)-, —N(C 0-6 alkyl)-C(O)—, —N(C 0-6 alkyl)-C(O)—N(C 0-6 alkyl-, —C(O)—, —CH(OH)—, —C═C—, —C≡C—, optionally substituted with 1-6 independent —CHO aryl, aryloxy-, —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)-C(O)—(C 0-6 alkyl), —OPO(OH)O-M + , —OSO 3 -M + , —O—CO(C 1-3 alkyl)CO 2 -M + , —O—CO—(C 1-6 alkyl)-N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—C 0-6 alkyl, —N(C 0-6 alkyl)-C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —C(O)—N( 0-6 alkyl)(C 0-6 alkyl), xvii) —S(O) 1-2 —(C 1-6 alkyl)-, xviii) —C 0-4 alkyl-C 3-6 cycloalkyl, or xix) —C 0-4 alkyl-O—C(O)—C 0-4 alkyl substituents;
Ar 2 is phenyl, optionally substituted with 1-5 independent i) halogen, ii) —CN, iii) —NO 2 , iv) —CHO, v) —O—C 1-4 alkyl, vi) —N(C 0-4 alkyl)(C 0-4 alkyl), vii) —C 0-4 alkyl-CO—O(C 0-4 alkyl), viii) —(C 0-4 alkyl)-NH—CO—O(C 0-4 alkyl), ix) x) —S(C 0-4 alkyl), xi) —S(O)(C 1-4 alkyl), xii) —SO 2 (C 1-4 alkyl), xiii) —SO 2 N(C 0-4 alkyl)(C 0-4 alkyl), xiv) —NHSO 2 (C 1-4 alkyl), xv) —C 1-10 alkyl optionally substituted with 1-6 independent —CHO, —O—C 1-4 alkyl, aryl, aryloxy-, —N(C 0-6 alkyl)(C 0-6 alkyl), —OPO(OH)O-M + , —OSO 3 -M + , —O—CO(C 1-3 alkyl)CO 2 -M + , —O—CO—(C 1-6 alkyl)-N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—C 0-6 alkyl, —N(C 0-6 alkyl)-C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), xvi) —C 1-10 alkyl in which one or more of the alkyl carbons is replaced by a —N(C 0-6 alkyl)-, —O—, —S(O) 1-2 —, —O—C(O)—, —C(O)—O—, —C(O)—N(C 0-6 alkyl)-, —N(C 0-6 alkyl)-C(O)—, —N(C 0-6 alkyl)-C(O)—N(C 0-6 alkyl-, —C(O)—, —CH(OH)—, —C═C—, —C≡C—, optionally substituted with 1-6 independent —CHO, aryl, aryloxy-, —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)-C(O)—(C 0-6 alkyl), —OPO(OH)O-M + , —OSO 3 -M + , —O—CO(C 1-3 alkyl)CO 2 M + , —O—CO—(C 1-6 alkyl)-N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—C 0-6 alkyl, —N(C 0-6 alkyl)-C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —C(O)—N( 0-6 alkyl)(C 0-6 alkyl), xvii) —S(O) 1-2 —(C 1-6 alkyl)-, xviii) —C 0-4 alkyl-C 3-6 cycloalkyl, or xix —C 0-4 alkyl-O—C(O)—C 0-4 alkyl substituents, provlded that when R 1 is hydrogen the substituents of Ar 2 cannot be halogen, —CN, —NO 2 , —O—C 1-4 alkyl, —NHSO 2 (C 1-4 alkyl), or —SO 2 (C 1-4 alkyl);
A is —O—, —S—, —CH 2 —, —N(C 0-4 alkyl)-, or absent;
wherein aryl is phenyl, optionally substituted with 1-6 independent i) halogen, ii) —CN, iii) —NO 2 , iv) —CHO, v) —O—C 1-4 alkyl, vi) —N(C 0-4 alkyl)(C 0-4 alkyl), vii) —C 0-4 alkyl-CO—O(C 0-4 alkyl), viii) —(C 0-4 alkyl)-NH—CO—O(C 0-4 alkyl, ix) —(C 0-4 alkyl)-CO—N(C 0-4 alkyl)(C 0-4 alkyl), x) —S(C 0-4 alkyl), xi) —S(O)(C 1-4 alkyl), xii) —SO 2 (C 1-4 alkyl), xii) —SO 2 N(C 0-6 alkyl)(C 0-4 alkyl), xiv) —NHSO 2 (C 1-4 alkyl), xv) —C 1-10 alkyl optionally substituted with 1-6 independent —CHO, —O—C 1-4 alkyl, aryl, aryloxy-, —N(C 1-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)-C(O)—C 0-6 alkyl), —OPO(OH)O-M + , —OSO 3 -M + , —O—CO(C 1-3 alkyl)CO 2 -M + , —O—CO—(C 1-6 alkyl)-N(C 0-6 alkyl)(C 0-6 alkyl, —O—C(O)—C 0-6 alkyl, —N(C 0-6 alkyl)-C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), xvi) —C 1-10 alkyl in which one or more of the alkyl carbons is replaced by a —N(C 0-6 alkyl)-, —O—, —S(O) 1-2 —, —O——C(O)—, —C(O)—O—, —C(O)—N(C 0-6 alkyl)-, —N(C 0-6 alkyl)-C(O)—, —N(C 0-6 alkyl)-C(O)—N(C 0-6 alkyl)-, —C(O)—, —CH(OH)—, —C═C—, —C≡C—, optionally substituted with 1-6 independent —CHO, aryl, aryloxy-, —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)-C(O)—(C 0-6 alkyl), —OPO(OH)O-M + , —OSO 3 -M + , —O—CO(C 1-3 alkyl)CO 2 -M + , O—CO—(C 1-6 alkyl)-N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—C 0-6 alkyl, —N(C 0-6 alkyl)-C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —O—C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), —C(O)—N(C 0-6 alkyl)(C 0-6 alkyl), xvii) —S(O) 1-2 —(C 1-6 alkyl)-, xviii) —C 0-4 alkyl-C 3-6 cycloalkyl, or xix) —C 0-4 alkyl-O—C(O)—C 0-4 alkyl substituents;
M + is arnmoniurn, sodium, lithium, potassium, calcium, magnesium, dicyclohexylamine, N-methyl-D-glucaniine, arginine, or lysine; and
any alkyl is optionally substituted with 1-6 independent halogen, phenyl, naphthyl, —N(C 0-4 alkyl)(C 0-4 alkyl), —C(O)—O(C 0-4 alkyl), —CN, —NH—C(O)—O(C 0-4 alkyl), —S(C 0-4 alkyl), —NHSO 2 (C 0-4 alkyl)(C 0-4 alkyl), or —SO 2 N(C 0-4 alkyl)(C 0-4 alkyl) substituent.
2. The method according to claim 1 wherein said compound is represented by Formula (IA), or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1 wherein said compound is represented by Formula (IB), or a pharmaceutically acceptable salt thereof.
4. A compound represented by
or a pharmaceutically acceptable salt thereof.
5. A compound represented by
Ra
Rc
(4-F)-phenoxy
(CH 3 ) 3 N + -CH 2 —CH 2
(3,4-methylene-dioxy)-phenoxy
(CH 3 ) 3 N + -CH 2 —CH 2
(4-Cl)-phenoxy-
(CH 3 ) 2 N—CH 2 —CH 2
(4-F)-phenoxy-
(i-Pr) 2 N—CH 2 —CH 2
(4-F)-phenoxy-
(CH 2 ) 4 N—CH 2 —CH 2
(4-F)-phenoxy-
(CH 3 ) 2 N—CH 2 CH(CH 3 )—
(4-F)-phenoxy-
(CH 3 ) 2 N—CH 2 CH 2 CH 2 —
(4-CF 3 )-phenoxy-
(CH 3 ) 2 N—CH 2 —CH 2
(4-F)-phenoxy-
N-morpholino-CH 2 —CH 2
(4-F)-phenoxy-
NH 2 C(O)—CH 2 —
(3,4-CH 3 O)-phenoxy-
HO—CH 2 —CH 2
(3,4-methylenedioxy)phenoxy-
H
(3,4-methylenedioxy)phenoxy-
(CH 3 ) 2 N—CH 2 —CH 2
(4-F)-phenoxy-
(CH 2 ) 5 N—CH 2 —CH 2
Ph
(CH 3 ) 2 N—CH 2 —CH 2
or a pharmaceutically acceptable salt thereof.
6. A compound represented by
R
4-(2-trfluoromethoxyphenyl-5-bromo)
3-(2-trifluoromethoxyphenyl-5-bromo)
3-(2-thiomethylphenyl)
3-(2-N,N-diisopropylphenyl)
3-(2-sulfinylmethylphenyl)
3-(2-N,N-dimethylphenyl)
3-(2-isopropylphenyl)
4-(2-t-butoxycarbonylphenyl
4-(2-t-butoxycarbonyl aminophenyl
4-(2-carboxy-phenyl)
3-(2-t-butoxycarbonylphenyl)
3-(2-OCH 2 CF 3 -phenyl)
4-(2-OCH 2 CF 3 -phenyl)
4-(2-phenoxyphenyl)
3-(2-phenoxyphenyl)
2-(2-phenoxyphenyl)
3-(2-benzyloxyphenyl)
4-(2-benzyloxyphenyl)
3-(2,5-bis-CF 3 phenyl)
4-(2,5-bis-CF 3 phenyl)
3-(3-CF 3 phenyl)
or a pharmaceutically acceptable salt thereof.
7. A compound represented by
R 1
R 2
R
4-dimethylamino
H
—SO 2 NHC(CH 3 ) 3
4-dimethylamino
H
—SO 2 NH 2
4-F
H
—SO 2 NHC(CH 3 ) 3
4-F
H
—SO 2 NH 2
4-phenyl
H
—SO 2 NHC(CH 3 ) 3
4-phenyl
H
—SO 2 NH 2
2-Cl
3-Cl
—SO 2 NHC(CH 3 ) 3
2-Cl
3-Cl
—SO 2 NH 2
4-(4-F)phenoxy
H
—SO 2 NHC(CH 3 ) 3
4-(4-F)phenoxy
H
—SO 2 NH 2
3-(4-Cl)phenoxy
H
—SO 2 NHC(CH 3 ) 3
3-(4-Cl)phenoxy
H
—SO 2 NH 2
4-CH 3 O
H
—SO 2 NHC(CH 3 ) 3
4-CH 3 O
H
—SO 2 NH 2
4-(3,4-methylene-dioxy)phenoxy
H
—SO 2 NHC(CH 3 ) 3
4-(3,4-methylene-dioxy)phenoxy
H
—SO 2 NH 2
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising: a therapeutically effective amount of the compound according to claim 4 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
9. A method of treatment of pain comprising the step of administering a therapeutically effective amount of the compound according to Formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, as defined in claim 1 .
10. A method of treatment of chronic, visceral, inflammatory and neuropathic pain comprising the step of administering a therapeutically effective amount of the compound according to Formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, as defined in claim 1 .
11. A method of treatment of pain resulting from traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeniinal neuralgia, diabetic neuropathy, chronic lower back pain, phantom limb pain, and pain resulting from cancer and chemotherapy comprising the step of administering a therapeutically effective amount of the compound according to Formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, as defined in claim 1 .
12. A pharmaceutical composition comprising: a compound according to claim 5 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.